Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc (NQ: XENE )

28.42 -0.72 (-2.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 417,399
Open 29.28
Bid (Size) 26.51 (1)
Ask (Size) 30.70 (1)
Prev. Close 29.14
Today's Range 28.10 - 29.77
52wk Range 14.65 - 36.42
Shares Outstanding 53,105,718
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Recap: Xenon Pharmaceuticals Q1 Earnings
Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga

Performance

YTD
-10.03%
-10.03%
1 Month
-11.71%
-11.71%
3 Month
-7.97%
-7.97%
6 Month
+4.75%
+4.75%
1 Year
+49.50%
+49.50%

More News

Read More
Swing Trading Stock Watchlist For April 11 And Beyond
Via Talk Markets
Earnings Scheduled For March 1, 2022
Via Benzinga
Earnings Scheduled For May 10, 2022
Via Benzinga
Swing Trading Stock Watchlist For April 4 And Beyond
Via Talk Markets
Xenon Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Recap: Xenon Pharmaceuticals Q4 Earnings
Via Benzinga
Xenon Pharmaceuticals's Earnings: A Preview
Via Benzinga
Xenon Receives $15M Regulatory Milestone Under Epilepsy Pact With Neurocrine
Via Benzinga
Wednesdays With Wedbush: Analyst Laura Chico On The State Of Biotech
Via Benzinga
Xenon Pharmaceuticals Scores As Epilepsy Results Highlight 'Competitive Profile'
Via Investor's Business Daily
Xenon Stock Jumps On New Encouraging Data From Epilepsy Treatment
Via Benzinga
The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering
Via Benzinga
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, & More
Via Talk Markets
Exposures COVID-19 Product Safety
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week
Via Benzinga
Exposures COVID-19 Product Safety
Xenon Pharmaceuticals Has a Great Story But Too High a Price
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2021
Via Benzinga
Xenon: Heading Toward Phase III With Strong Momentum
Via InvestorPlace
New Clinical Results Make Xenon Pharmaceuticals’ Stock Worthy Again
Via InvestorPlace
Shares of Xenon Pharmaceuticals Inc. Have Risen Above Previous 52-Week High
Via Benzinga
3 Growth Stocks Near 52-Week Highs to Buy Anyway
Via The Motley Fool
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.